FDA Sentinel Initiative Needs Safeguards To Protect Industry And Patients
This article was originally published in The Gray Sheet
Executive Summary
A greatly expanded drug and device surveillance program could do more harm than good without proper safeguards in place, according to participants at a Dec. 16 FDA-sponsored workshop
You may also be interested in...
Regulatory News In Brief
FDA may publicize inspection reports: FDA is seeking input on whether it should publicly disclose key findings from inspection reports. Currently, Form 483 reports, which list observations made during an inspection of a firm, are not made public. Freedom of Information Act requests for the reports can take a long time because of the need to redact confidential trade secret information, FDA notes. In a Nov. 21 post on its 1Transparency Blog, FDA asks whether the reports should be redesigned to separate out a summary or key findings page that could quickly be made publicly available. Three commenters on the post supported the concept
Regulatory News In Brief
FDA may publicize inspection reports: FDA is seeking input on whether it should publicly disclose key findings from inspection reports. Currently, Form 483 reports, which list observations made during an inspection of a firm, are not made public. Freedom of Information Act requests for the reports can take a long time because of the need to redact confidential trade secret information, FDA notes. In a Nov. 21 post on its 1Transparency Blog, FDA asks whether the reports should be redesigned to separate out a summary or key findings page that could quickly be made publicly available. Three commenters on the post supported the concept
NEJM Editorialists: Sentinel System Feasible, But Presents Challenges
FDA's post-market surveillance Sentinel Initiative comes with some steep challenges, several health policy experts write in the New England Journal of Medicine July 27